In Phase 2 clinical trials, retatrutide was administered as a once-weekly subcutaneous injection using a structured dose-escalation schedule to improve gastrointestinal tolerability
We delineated the molecular cascade linking BPC157 engagement to upregulated proangiogenic factor expression, thereby establishing a comprehensive mechanistic framework for its therapeutic actions
Seven additional phase 3 readouts are expected throughout this year, covering a range of conditions including type 2 diabetes, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic dysfunction-associated steatotic liver disease
Moreover, no fibrotic changes were observed in the liver [135]
They're not hype
What Clinical Studies Suggest Clinical studies have shown that tirzepatide can help reduce HbA1c levels and support greater weight loss compared with semaglutide 1 mg in adults with type 2 diabetes